Trabectedin: Supportive care strategies and safety profile

Critical Reviews in Oncology/hematology
Karin JordanJörn Rüssel

Abstract

Trabectedin is an approved antineoplastic agent for the treatment of adult patients with advanced soft tissue sarcomas or in combination with pegylated liposomal doxorubicin (PLD) in patients with relapsed platinum sensitive ovarian cancer. The mechanism of action is still not fully understood but many typical side effects seen with other chemotherapy drugs are less common, mild or unreported. Although this apparent favorable safety profile suggests a well-tolerated and manageable therapeutic option in the palliative care setting, trabectedin does have specific adverse side effects which can be hazardous for individual patients. The most commonly observed toxicities with trabectedin include neutropenia, nausea, vomiting, and increases in liver transaminases, anemia, fatigue, thrombocytopenia, anorexia and diarrhea. However, for most patients the appropriate use of supportive care strategies can reduce or overcome these side effects. We present a concise review of the safety data of trabectedin with the corresponding overview of the supportive care strategies.

References

Feb 20, 2004·Journal of Clinical Pharmacology·Craig R ShadleRobert A Blum
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A YovineJ L Misset
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Garcia-CarboneroG D Demetri
Mar 8, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·J H BeumerJ H Beijnen
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cristiana SessaNicoletta Colombo
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Garcia-CarboneroG D Demetri
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J SmithAntonio C Wolff
Jun 2, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F GrossoP G Casali
Jul 7, 2007·The Lancet Oncology·Margaret von Mehren
May 24, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M von MehrenR B Cohen
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Todd A ThemanSuzanne George
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F RoilaUNKNOWN ESMO/MASCC Guidelines Working Group
Jul 22, 2010·Molecular Cancer Therapeutics·Maurizio D'Incalci, Carlos M Galmarini
Aug 31, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ian OlverKarin Jordan
Nov 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer
Mar 19, 2011·Cancer Chemotherapy and Pharmacology·Claudia LebedinskyCarmen Kahatt
Jul 9, 2011·Cancer Chemotherapy and Pharmacology·R ThertulienA P Staddon
Mar 2, 2012·Journal of Oncology Practice·Ethan BaschGary H Lyman
Jul 4, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Axel Le CesneGeorge D Demetri
Jan 11, 2013·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·J A Pérez FidalgoUNKNOWN ESMO Guidelines Working Group
Jul 16, 2013·Journal of the National Cancer Institute·Debra L BartonCharles L Loprinzi
Jul 31, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sriram YennurajalingamEduardo Bruera
Aug 14, 2013·Expert Opinion on Drug Safety·Juan Martin-Liberal, Ian Judson
Jan 24, 2014·Future Oncology·Ioannis GounarisHelena M Earl
Sep 12, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Christian LeporiniEmilio Russo

❮ Previous
Next ❯

Citations

Jun 22, 2016·Expert Opinion on Pharmacotherapy·Rita De SanctisArmando Santoro
Jun 3, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gabriella FerrandinaGiovanni Scambia
Jan 20, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Marilena Di NapoliSabrina Chiara Cecere

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.